SCHEMBL18053161

SCHEMBL18053161

Cc1nc(NC(C)C)ccc1C#N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDH1 O75874 13/20 0.48
▸ IRAK4 Q9NWZ3 1/20 0.42
▸ F2 P00734 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ LRRK2 Q5S007 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ GLA P06280 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ CASP1 P29466 1/20 0.38
▸ CLK1 P49759 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ PDE10A Q9Y233 1/20 0.36
▸ ABCB1 P08183 1/20 0.36
▸ ABCC1 P33527 1/20 0.36
▸ ABCG2 Q9UNQ0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14382398 0.79 IDH1 (0.43) IDH1KDM4EABCG2IDO1
SCHEMBL424758 0.78 IDH1 (0.40) IDH1KDM4EALDH1A1GAAABCG2
SCHEMBL25150667 0.75 NOS3 (0.41) KDM4EALDH1A1GAAPDE10A
SCHEMBL23013221 0.72 RAB9A (0.44) LMNAMAPK1KDM4EALDH1A1HSD17B10
SCHEMBL23023572 0.72 PDE10A (0.39) LMNAALDH1A1GAAPDE10A
SCHEMBL12775196 0.72 KDM5A (0.36) IDH1MAPK1KDM4EALDH1A1L3MBTL1
SCHEMBL21339510 0.70 KCNJ1 (0.36) IDH1MAPK1KDM4EALDH1A1L3MBTL1
SCHEMBL18053165 0.70 KDM4E (0.43) F2LMNAMAPK1HTTKDM4E
SCHEMBL5127366 0.70 IDH1 (0.43) IDH1IRAK4KDM4E
SCHEMBL31253097 0.70 HRH4 (0.45) KDM4EALDH1A1GAAHPGDL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170354656-A1 Quinazoline Compounds INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) 2017-12-14 — — US disclosed
US-9730936-B2 Quinazoline compounds GILEAD SCIENCES, INC. (US) 2017-08-15 — — US disclosed
US-9730936-B2 Quinazoline compounds GILEAD SCIENCES, INC. (US) 2017-08-15 — — US disclosed
US-20160250215-A1 QUINAZOLINE COMPOUNDS INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) 2016-09-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160250215-A1 QUINAZOLINE COMPOUNDS TTBK1, TTBK2, MAPT IDH1 1218/4885IRAK4 3811/4885F2 919/4885
US-20170354656-A1 Quinazoline Compounds TTBK1, TTBK2, MAPT IDH1 1218/4885IRAK4 3811/4885F2 919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback